{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T07:39:09Z","timestamp":1648712349595},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,9,26]],"date-time":"2011-09-26T00:00:00Z","timestamp":1316995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,9,26]],"date-time":"2011-09-26T00:00:00Z","timestamp":1316995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1038\/bmt.2011.193","type":"journal-article","created":{"date-parts":[[2011,9,26]],"date-time":"2011-09-26T14:56:56Z","timestamp":1317049016000},"page":"877-879","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment with tandem consolidation using 90yttrium-ibritumomab tiuxetan (Zevalin) and high-dose therapy with autologous PBSCT in a patient with relapsed mantle cell lymphoma presenting as multiple lymphomatous polyposis"],"prefix":"10.1038","volume":"47","author":[{"given":"E J","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S-A","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-S","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J I","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-S","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S-G","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,26]]},"reference":[{"key":"BFbmt2011193_CR1","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1200\/JCO.2007.14.9856","volume":"26","author":"S Michopoulos","year":"2008","unstructured":"Michopoulos S, Petraki K, Matsouka C, Kastritis E, Chrysanthopoulou H, Dimopoulos MA . Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract. J Clin Oncol 2008; 26: 1555\u20131557.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011193_CR2","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","volume":"114","author":"M Ghielmini","year":"2009","unstructured":"Ghielmini M, Zucca E . How I treat mantle cell lymphoma. Blood 2009; 114: 1469\u20131476.","journal-title":"Blood"},{"key":"BFbmt2011193_CR3","first-page":"117","volume":"19","author":"M Meral","year":"2008","unstructured":"Meral M, Demirpence M, Gonen C, Akarsu M, Kayahan H, Demirkan F et al. Diffuse gastrointestinal involvement of mantle cell lymphoma. Turk J Gastroenterol 2008; 19: 117\u2013120.","journal-title":"Turk J Gastroenterol"},{"key":"BFbmt2011193_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/cncr.11096","volume":"97","author":"JE Romaguera","year":"2003","unstructured":"Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003; 97: 586\u2013591.","journal-title":"Cancer"},{"key":"BFbmt2011193_CR5","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.3748\/wjg.v16.i37.4661","volume":"16","author":"M Iwamuro","year":"2010","unstructured":"Iwamuro M, Okada H, Kawahara Y, Shinagawa K, Morito T, Yoshino T et al. Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement. World J Gastroenterol 2010; 16: 4661\u20134669.","journal-title":"World J Gastroenterol"},{"key":"BFbmt2011193_CR6","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/asheducation-2009.1.542","volume":"1","author":"M Dreyling","year":"2009","unstructured":"Dreyling M, Hiddemann W . Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009; 1: 542\u2013551.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFbmt2011193_CR7","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453\u20132463.","journal-title":"J Clin Oncol"},{"key":"BFbmt2011193_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1349-7006.2008.00999.x","volume":"100","author":"K Tobinai","year":"2009","unstructured":"Tobinai K, Watanabe T, Ogura M, Morishima Y, Hotta T, Ishizawa K et al. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 2009; 100: 158\u2013164.","journal-title":"Cancer Sci"},{"key":"BFbmt2011193_CR9","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","volume":"27","author":"M Wang","year":"2009","unstructured":"Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 5213\u20135218.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2011193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2011193","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2011193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T14:34:10Z","timestamp":1648046050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2011193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,26]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["BFbmt2011193"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2011.193","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,26]]},"assertion":[{"value":"26 September 2011","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}